Neuramedy
Neuramedy provides research on neurodegenerative disorders focused on alpha-synuclein and related mechanisms for Parkinson's disease.
Neuramedy is active in the biotechnology, market research, medical, professional services space based in Asia-Pacific (APAC), founded in 2019.
Within the biotechnology, market research, medical, professional services space, the company focuses on its core offering rather than a broad product line.
The company is recorded as being based in Asia-Pacific (APAC).
The company is listed at the Series_A stage of development.
Recorded headcount: c_00011_00050 employees.
Total disclosed funding stands at about $8B.
| Sector | Biotechnology, Market Research, Medical, Professional Services |
|---|---|
| Headquarters | Asia-Pacific (APAC) |
| Country | KR |
| Founded | 2019 |
| Employees | c_00011_00050 |
| Stage | series_a |
| Total funding | $8,000,000,000 |
Website: www.neuramedy.com
Browse related
Sign in to view the contact information we hold for Neuramedy.
Create a free account
Create a free account